Immunotherapy for Infectious Diseases

Recommendations

Info

Production of Igs and MAbs Targeting Infectious Diseases 97 138. Gaida T, et al. Selective retention of viable cells in ultrasonic resonance field devices. Biotechnol Prog 1996; 12:73–76. 139. Banik GG, Heath CA. Partial and total cell retention in a filtration-based homogeneous perfusion reactor. Biotechnol Prog 1995; 11:584–588. 140. Bliem R, et al. Performance characteristics of mammalian cell culture process operating continuously with protein-free medium. Appl Biochem Biotechnol 1990; 26:217–229. 141. Amersham PB. Evaluating virus removal/inactivation in a process to purify anti-HIV-1 human monoclonal antibody by expanded bed adsorption with STREAMLINE rProteinA. Application note, 1998.
Page 1 and 2:
Immunotherapy for Infectious Diseas
Page 3 and 4:
In f e c t i o u s . D i s e a s e
Page 5 and 6:
© 2002 Humana Press Inc. 999 River
Page 7 and 8:
vi Preface I am grateful to all of
Page 9 and 10:
viii Contents 11 Passive Immunother
Page 11 and 12:
x Contributors BARBARA G. MATTHEWS,
Page 14 and 15:
From: Immunotherapy for Infectious
Page 16 and 17:
Humoral Immunity 5 Fig. 1. Humoral
Page 18 and 19:
Humoral Immunity 7 Table 1 Properti
Page 20 and 21:
Humoral Immunity 9 minal complement
Page 22 and 23:
Humoral Immunity 11 ficity. In ligh
Page 24 and 25:
Humoral Immunity 13 Fig. 7. VDJ joi
Page 26 and 27:
Humoral Immunity 15 Fig. 9. Messeng
Page 28 and 29:
Humoral Immunity 17 In contrast to
Page 30 and 31:
Humoral Immunity 19 advantage to tr
Page 32 and 33:
Humoral Immunity 21 32. Allman DM,
Page 34 and 35:
Some Basic Cellular Immunology Prin
Page 36 and 37:
Cellular Immunology Principles 25 i
Page 38 and 39:
Cellular Immunology Principles 27 s
Page 40 and 41:
Cellular Immunology Principles 29 d
Page 42 and 43:
Cellular Immunology Principles 31 f
Page 44 and 45:
Cellular Immunology Principles 33 F
Page 46 and 47:
Cellular Immunology Principles 35 R
Page 48 and 49:
Cellular Immunology Principles 37 1
Page 50 and 51:
INTRODUCTION Immune Defense at Muco
Page 52 and 53:
Immune Defense at Mucosal Surfaces
Page 54 and 55:
Page 56 and 57:
Page 58 and 59: Immune Defense at Mucosal Surfaces
Page 72: II Molecular Basis for Immunotherap
Page 75 and 76: 64 Kunert and Katinger IMMUNOGLOBUL
Page 77 and 78: 66 Fig. 2. Monomeric, dimeric, and
Page 79 and 80: 68 Kunert and Katinger Fig. 4. Humo
Page 81 and 82: 70 Kunert and Katinger remove prote
Page 83 and 84: 72 Kunert and Katinger Fig. 6. Diff
Page 85 and 86: 74 Kunert and Katinger persons of a
Page 87 and 88: 76 Kunert and Katinger that so-call
Page 89 and 90: 78 Kunert and Katinger whereas sele
Page 91 and 92: 80 Kunert and Katinger Different pr
Page 93 and 94: 82 Kunert and Katinger HUMAN/MOUSE
Page 95 and 96: 84 Kunert and Katinger are expresse
Page 97 and 98: 86 Kunert and Katinger missing meta
Page 99 and 100: 88 Kunert and Katinger Fig. 8. Sche
Page 101 and 102: 90 Kunert and Katinger include a se
Page 103 and 104: 92 Kunert and Katinger 32. Lee S, e
Page 105 and 106: 94 Kunert and Katinger 72. Abbs IC,
Page 107: 96 Kunert and Katinger 117. Wright
Page 111 and 112: 100 Kundu-Raychaudhuri and Engleman
Page 129 and 130: 118 Matthews Cytokines can target a
Page 131 and 132: 120 Matthews Table 1 Source and Act
Page 133 and 134: 122 Matthews The Jak-Stat Model of
Page 135 and 136: 124 Matthews and heart. Interesting
Page 137 and 138: 126 Matthews In humans, Th1 cells p
Page 139 and 140: 128 Matthews 20. Taub DD, Oppenheim
Page 141 and 142: 130 Bona The immune system is compo
Page 143 and 144: 132 Bona Fig. 2. Intracellular mech
Page 145 and 146: 134 Bona Subunit Vaccines Subunit v
Page 147 and 148: 136 Bona Table 4 Live Attenuated Va
Page 149 and 150: 138 Bona Recombinant Vectors Vaccin
Page 151 and 152: 140 Bona Table 6 DNA Vaccines Used
Page 153 and 154: 142 Bona Fig. 3. Mechanisms of acti
Page 155 and 156: 144 Bona Fig. 5. Mechanism of gener
Page 157 and 158: 146 Bona Fig. 7. Structure of self
Page 160:
III Immunotherapy for HIV Infection
Page 163 and 164:
152 Fox Scope of the Epidemic World
Page 165 and 166:
154 Fox receptor binding by the V3
Page 167 and 168:
156 Fox plasma cells. Failure of th
Page 169 and 170:
158 Fox Challenges of Therapeutic T
Page 171 and 172:
160 Fox REFERENCES 1. UNAIDS. Repor
Page 174 and 175:
INTRODUCTION Immune Reconstitution
Page 176 and 177:
Immune Reconstitution with Antiretr
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190:
Page 193 and 194:
182 Kalams model, immune control is
Page 195 and 196:
184 Kalams complexed with HLA class
Page 197 and 198:
186 Kalams caused by an increase in
Page 199 and 200:
188 Kalams series of treatment inte
Page 201 and 202:
190 Kalams Another promising approa
Page 203 and 204:
192 Kalams 29. Brander C, Hartman K
Page 205 and 206:
194 Kalams 66. Altfeld M, Rosenberg
Page 207 and 208:
196 Kalams virus infection. Militar
Page 210 and 211:
INTRODUCTION From: Immunotherapy fo
Page 212 and 213:
Passive Immunotherapy for HIV Infec
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Host Cell-Directed Approaches 223 C
Page 236 and 237:
Host Cell-Directed Approaches 225 s
Page 238 and 239:
Host Cell-Directed Approaches 227 a
Page 240 and 241:
Host Cell-Directed Approaches 229 t
Page 242 and 243:
Host Cell-Directed Approaches 231 R
Page 244 and 245:
Host Cell-Directed Approaches 233 4
Page 246 and 247:
Host Cell-Directed Approaches 235 8
Page 248 and 249:
Page 250 and 251:
Gene Therapy for HIV-1 Infection 23
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260:
IV Immunotherapy for Infectious Dis
Page 263 and 264:
252 Onorato and Pollard However, th
Page 265 and 266:
254 Onorato and Pollard patients wi
Page 267 and 268:
256 Onorato and Pollard Another imm
Page 269 and 270:
258 Onorato and Pollard 26. Guidott
Page 271 and 272:
260 Sili, Heslop, and Rooney Fig. 1
Page 273 and 274:
Page 275 and 276:
264 Sili, Heslop, and Rooney immuno
Page 277 and 278:
Page 279 and 280:
268 Sili, Heslop, and Rooney Human
Page 281 and 282:
270 Sili, Heslop, and Rooney CONCLU
Page 283 and 284:
272 Sili, Heslop, and Rooney 32. Ba
Page 285 and 286:
274 Sili, Heslop, and Rooney 73. va
Page 287 and 288:
276 Donta no controlled clinical tr
Page 289 and 290:
278 Donta antibody preparation (HA-
Page 291 and 292:
280 Donta 16. Salcedo J, Keates S,
Page 294 and 295:
Page 296 and 297:
Tuberculosis and Other Mycobacteria
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Fungal Infections 305 Table 2 Categ
Page 318 and 319:
Fungal Infections 307 rapid bone ma
Page 320 and 321:
Fungal Infections 309 has activity
Page 322 and 323:
311 Table 4 Case Reports of Unusual
Page 324 and 325:
Fungal Infections 313 randomized co
Page 326 and 327:
Fungal Infections 315 the administr
Page 328 and 329:
Fungal Infections 317 modalities in
Page 330 and 331:
Fungal Infections 319 35. Vecchiare
Page 332 and 333:
Fungal Infections 321 74. Han Y, Cu
Page 334 and 335:
Index 323 A ADCC, see Antibody-depe
Page 336 and 337:
Index 325 immunotherapy clinical tr
Page 338 and 339:
Index 327 function, 32, 33, 182-185
Page 340 and 341:
Index 329 secretory immunoglobulin
Page 342 and 343:
Index 331 dendritic cell response,
show all

Immunotherapy for Infectious Diseases

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?